Cyclophosphamide + Epidoxorubicin + Filgrastim + Fluorouracil

This is a chemotherapy combination regimen primarily used in cancer treatment. It includes: * **Cyclophosphamide**: An alkylating agent that requires activation in the liver to form aldophosphamide. It is used in various cancers, including breast carcinoma, lymphomas, myelomas, and leukemia. * **Epidoxorubicin**: A variant of doxorubicin, an anthracycline commonly used in chemotherapy regimens. While not explicitly detailed in the provided text, its class suggests it functions as a topoisomerase inhibitor and DNA intercalator. * **Fluorouracil (5-FU)**: An antimetabolite that acts as a pyrimidine antagonist. It is frequently combined with cyclophosphamide and doxorubicin in breast cancer protocols. * **Filgrastim (G-CSF)**: A granulocyte colony-stimulating factor that is typically added to these regimens to manage chemotherapy-induced neutropenia, a common side effect. Similar regimens mentioned in the search results include FLAC (Fluorouracil, Folinic acid, Doxorubicin, Cyclophosphamide) and a combination of Cyclophosphamide, Doxorubicin, Fluorouracil, and Filgrastim. These combinations are notably used in breast cancer treatment, where "dose intensity appears to be an important factor influencing clinical outcome in early node-positive breast cancer." Though primarily associated with breast cancer, this combination may have applications in other cancers as well. Dosing protocols vary, with examples given for related regimens (e.g., Cyclophosphamide: 100 mg/m² orally on days 1-14; Fluorouracil: 600 mg/m² IV on days 1 and 8).

Other names

FEC regimen with G-CSF support